Evidence map›Paper›PMID 25133893›Full record

ReviewBone marrow transplantation2014

Not too little, not too much-just right! (Better ways to give high dose melphalan).

P J Shaw, C E Nath, H M Lazarus

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Melphalan 140 mg/mHaematologica · 2018
    Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

P J Shaw1] Departments of Oncology The Children's Hospital at Westmead, Westmead, New South Wales, Australia [2] The Department of Paediatrics and Child Health, University of Sydney, Sydney, New South Wales, Australia.
C E Nath1] Departments of Oncology The Children's Hospital at Westmead, Westmead, New South Wales, Australia [2] Biochemistry The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
H M LazarusDepartment of Medicine, Division of Haematology-Oncology, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Of the 13 286 autologous haematopoietic cell transplant procedures reported in the US in 2010-2012 for plasma cell disorders, 10 557 used single agent, high-dose melphalan. Despite 30 years of clinical and pharmacokinetic (PK) experience with high-dose melphalan, and its continuing central role as cytoreductive therapy for large numbers of patients with myeloma, the pharmacodynamics and pharmacogenomics of melphalan are still in their infancy. The addition of protectant agents such as amifostine and palifermin allows dose escalation to 280 mg/m(2), but at these doses it is cardiac, rather than gut, toxicity that is dose-limiting. Although combination with additional alkylating agents is feasible, the additional TRM may not be justified when so many post-consolidation therapies are available for myeloma patients. Current research should optimise the delivery of this single-agent chemotherapy. This includes the use of newer formulations and real-time PKs. These strategies may allow a safe and effective platform for adding synergistic novel therapies and provide a window of lymphodepletion for the addition of immunotherapies.

Indexed as

Hematopoietic Stem Cell TransplantationAmifostineAntineoplastic Agents, AlkylatingFibroblast Growth Factor 7HumansImmunosuppressive AgentsMelphalanMultiple MyelomaNeoplasmsObesityReproducibility of ResultsAmifostineAntineoplastic Agents, AlkylatingFibroblast Growth Factor 7Immunosuppressive AgentsMelphalan

Identifiers

PMID25133893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.